NRx Pharmaceuticals, Inc.

NASDAQ:NRXP

Biotechnology

Healthcare
$2.80 +1.43%

+$0.06 today

Market cap
$124.12M
Beta
2.19
P/E (TTM)
-5.3
EPS (TTM)
-$0.76
52W Low $1.62High $5.06

Volume 2.09M

Average 1.27M

NRXP Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

NRx Pharmaceuticals, Inc.NASDAQ: NRXP

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 32.33M shares rose 97.0% year over year, behind the +115.3% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 1.9% from the prior quarter. Over 3 fiscal years it compounded at -31.2% a year.

Context

  • Weighted avg shares increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +97.0% toward the trailing-twelve-month pace of +115.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
32.33M+1.9% QoQ
Last fiscal yearDec 2025
21.4M+103.5% YoY
LTMMar 2026
26.06M+115.3% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+97.0%——
1 year+103.5%——
3-year CAGR-31.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
21.4M USD
Year-over-year change
+103.5%
4-year CAGR
-17.8%

Weighted Avg Shares vs competitors

How NRXP compares with its peers on the latest reported figures

  • NRXP's LTM Mar 2026 weighted avg shares of 26.06M shares is the 5th highest of the 9 companies compared; the peer median is 30.75M shares.
  • Its year-over-year change of +115.3% is the 2nd highest of 9, against a peer median of +62.0%.
  • Over three fiscal years its annual growth of -31.2% compares with a peer median of +21.4%.
NRXP Competitors Peer median
Weighted Avg Shares for NRXP and competitors
Company Period LTM YoY 3-year CAGR
IPSCCentury Therapeutics, Inc.LTM Mar 202686.45M +4.3%+14.4%
EQEquillium, Inc.LTM Mar 202664.9M +83.3%+39.7%
OTLKOutlook Therapeutics, Inc.LTM Mar 202653.45M +120.6%+48.6%
HOWLWerewolf Therapeutics, Inc.LTM Jun 202647.17M +6.0%+16.8%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 202626.06M +115.3%-31.2%
KPTIKaryopharm Therapeutics Inc.LTM Mar 202614.32M +72.2%+26.1%
COEPCoeptis Therapeutics, Inc.LTM Mar 20264.68M -77.3%-33.3%
CUECue Biopharma, Inc.LTM Mar 20263.74M +79.5%+38.5%
SPRBSpruce Biosciences, Inc.LTM Mar 2026827.01K +51.8%+7.8%
Peer median (excluding NRXP) 30.75M+62.0%+21.4%

Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00001.23M
Cost of Revenue2K4K5K5K505K
Gross Profit(2K)(4K)(5K)(5K)720K
Gross Margin————58.8%
Research & Development20.26M17.03M13.37M6.2M3.78M
Selling, General & Admin74.94M27.3M14.21M13.5M13.06M
Operating Expenses95.2M44.33M27.58M19.7M16.94M
Depreciation & Amortization2K4K5K5K143K
EBITDA(93.04M)(39.75M)(30.03M)(24.04M)(27.81M)
EBITDA Margin————-2270.0%
Operating Income(95.2M)(44.34M)(27.59M)(19.7M)(16.22M)
Operating Margin————-1324.4%
Interest Income18249K494K44K12K
Interest Expense18K0120K1.08M671K
Other Income / Expenses2.14M4.58M(2.56M)(5.42M)(12.4M)
Income Before Tax(93.06M)(39.75M)(30.15M)(25.13M)(28.62M)
Pre-Tax Margin————-2336.5%
Income Tax Expense00000
Net Income(93.06M)(39.75M)(30.15M)(25.13M)(28.62M)
Net Margin————-2336.5%
EPS (Basic)(7.44)(0.60)(3.98)(2.39)(1.34)
EPS (Diluted)(7.44)(0.60)(3.98)(2.39)(1.34)
Weighted Avg Shares46.92M65.77M7.58M10.52M21.4M
Weighted Avg Shares (Diluted)46.92M65.77M7.58M10.52M21.4M

NRx Pharmaceuticals, Inc.

NASDAQ:NRXP

Intrinsic Alpha fair value

Locked

Current Price

$2.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.